- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 40FR12B Initial registration of securities (Canada)
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 99.12 Exhibit 99.12
- 99.13 Exhibit 99.13
- 99.14 Exhibit 99.14
- 99.15 Exhibit 99.15
- 99.16 Exhibit 99.16
- 99.17 Exhibit 99.17
- 99.18 Exhibit 99.18
- 99.19 Exhibit 99.19
- 99.20 Exhibit 99.20
- 99.21 Exhibit 99.21
- 99.22 Exhibit 99.22
- 99.23 Exhibit 99.23
- 99.24 Exhibit 99.24
- 99.25 Exhibit 99.25
- 99.26 Exhibit 99.26
- 99.27 Exhibit 99.27
- 99.28 Exhibit 99.28
- 99.29 Exhibit 99.29
- 99.30 Exhibit 99.30
- 99.31 Exhibit 99.31
- 99.32 Exhibit 99.32
- 99.33 Exhibit 99.33
- 99.34 Exhibit 99.34
- 99.35 Exhibit 99.35
- 99.36 Exhibit 99.36
- 99.37 Exhibit 99.37
- 99.38 Exhibit 99.38
- 99.39 Exhibit 99.39
- 99.40 Exhibit 99.40
- 99.41 Exhibit 99.41
- 99.42 Exhibit 99.42
- 99.43 Exhibit 99.43
- 99.44 Exhibit 99.44
- 99.45 Exhibit 99.45
- 99.46 Exhibit 99.46
- 99.47 Exhibit 99.47
- 99.48 Exhibit 99.48
- 99.49 Exhibit 99.49
- 99.50 Exhibit 99.50
- 99.51 Exhibit 99.51
- 99.52 Exhibit 99.52
- 99.53 Exhibit 99.53
- 99.54 Exhibit 99.54
- 99.55 Exhibit 99.55
- 99.56 Exhibit 99.56
- 99.57 Exhibit 99.57
- 99.58 Exhibit 99.58
- 99.59 Exhibit 99.59
- 99.60 Exhibit 99.60
- 99.61 Exhibit 99.61
- 99.62 Exhibit 99.62
- 99.63 Exhibit 99.63
- 99.64 Exhibit 99.64
- 99.65 Exhibit 99.65
- 99.66 Exhibit 99.66
- 99.67 Exhibit 99.67
- 99.68 Exhibit 99.68
- 99.69 Exhibit 99.69
- 99.70 Exhibit 99.70
- 99.71 Exhibit 99.71
- 99.72 Exhibit 99.72
- 99.73 Exhibit 99.73
- 99.74 Exhibit 99.74
- 99.75 Exhibit 99.75
- 99.76 Exhibit 99.76
- 99.77 Exhibit 99.77
- 99.78 Exhibit 99.78
- 99.79 Exhibit 99.79
- 99.80 Exhibit 99.80
- 99.81 Exhibit 99.81
- 99.82 Exhibit 99.82
- 99.83 Exhibit 99.83
- 99.84 Exhibit 99.84
- 99.85 Exhibit 99.85
- 99.86 Exhibit 99.86
- 99.87 Exhibit 99.87
- 99.88 Exhibit 99.88
- 99.89 Exhibit 99.89
- 99.90 Exhibit 99.90
- 99.91 Exhibit 99.91
- 99.92 Exhibit 99.92
- 99.93 Exhibit 99.93
- 99.94 Exhibit 99.94
- 99.95 Exhibit 99.95
- 99.96 Exhibit 99.96
- 99.97 Exhibit 99.97
- 99.98 Exhibit 99.98
- 99.99 Exhibit 99.99
- 99.100 Exhibit 99.100
- 99.101 Exhibit 99.101
- 99.102 Exhibit 99.102
- 99.103 Exhibit 99.103
- 99.104 Exhibit 99.104
- 99.105 Exhibit 99.105
- 99.106 Exhibit 99.106
- 99.107 Exhibit 99.107
- 99.108 Exhibit 99.108
- 99.109 Exhibit 99.109
- 99.110 Exhibit 99.110
- 99.111 Exhibit 99.111
- 99.112 Exhibit 99.112
- 99.113 Exhibit 99.113
- 99.114 Exhibit 99.114
- 99.115 Exhibit 99.115
- 99.116 Exhibit 99.116
- 99.117 Exhibit 99.117
- 99.118 Exhibit 99.118
- 99.119 Exhibit 99.119
- 99.120 Exhibit 99.120
- 99.121 Exhibit 99.121
- 99.122 Exhibit 99.122
- 99.123 Exhibit 99.123
- 99.124 Exhibit 99.124
- 99.125 Exhibit 99.125
- 99.126 Exhibit 99.126
- 99.127 Exhibit 99.127
- 99.128 Exhibit 99.128
- 99.129 Exhibit 99.129
- 99.130 Exhibit 99.130
- 99.131 Exhibit 99.131
- 99.132 Exhibit 99.132
- 99.133 Exhibit 99.133
- 99.134 Exhibit 99.134
- 99.135 Exhibit 99.135
- 99.136 Exhibit 99.136
- 99.137 Exhibit 99.137
- 99.138 Exhibit 99.138
- 99.139 Exhibit 99.139
- 99.140 Exhibit 99.140
- 99.141 Exhibit 99.141
- 99.142 Exhibit 99.142
- 99.143 Exhibit 99.143
- 99.144 Exhibit 99.144
- 99.145 Exhibit 99.145
- 99.146 Exhibit 99.146
- 99.147 Exhibit 99.147
- 99.148 Exhibit 99.148
- 99.149 Exhibit 99.149
- 99.150 Exhibit 99.150
- 99.151 Exhibit 99.151
- 99.152 Exhibit 99.152
- 99.153 Exhibit 99.153
- 99.154 Exhibit 99.154
- 99.155 Exhibit 99.155
- 99.156 Exhibit 99.156
- 99.157 Exhibit 99.157
- 99.158 Exhibit 99.158
- 99.159 Exhibit 99.159
- 99.160 Exhibit 99.160
- 99.161 Exhibit 99.161
- 99.162 Exhibit 99.162
- 99.163 Exhibit 99.163
- 99.164 Exhibit 99.164
- 99.165 Exhibit 99.165
- 99.166 Exhibit 99.166
- 99.167 Exhibit 99.167
- 99.168 Exhibit 99.168
- 99.169 Exhibit 99.169
- 99.170 Exhibit 99.170
- 99.171 Exhibit 99.171
- 99.172 Exhibit 99.172
- 99.173 Exhibit 99.173
- 99.174 Exhibit 99.174
ZEN Graphene Solutions Finalizes Definitive Commercial
Agreement with Trebor Rx
Guelph, ON - September 27, 2021, ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSX-V: ZEN and OTC: ZENYF), a Canadian, nanotechnology company focused on next-gen healthcare solutions, announces that it has signed a definitive commercial agreement with Trebor Rx (Trebor) for the manufacturing of ZENGuard™-enhanced personal protective equipment. The agreement includes surgical masks, filters for Trebor's patent pending Pro+ mask, nitrile gloves and other potential products.
Greg Fenton CEO commented: ''After working closely with George Irwin and the Trebor team over the last year, we have developed an excellent working relationship and are eager to launch our first product together, the Trebor Rx surgical mask with ZENGuard™ technology delivering over 99.99% bacterial and viral filtration efficiency. This is a significant commercial success for both our organizations, but more importantly, it brings a new option to healthcare employees and others in higher risk settings that wish to significantly enhance the bacterial and viral filtration efficiency compared to a typical, disposable ASTM level 3 mask.''
''Trebor and Zen have worked hard to bring a game changing mask to market. The enhanced protection in our mask is just the beginning of an extensive line of anti-microbial protective equipment designed to keep front line healthcare workers safer. The Trebor/Zen relationship is an example of two Canadian companies working together to develop, produce, market and sell world class product on the world stage.We are excited to be part of this journey with Greg Fenton, Francis Dube and the Zen group. '' commented George Irwin of Trebor Rx.
About ZEN Graphene Solutions Ltd.
ZEN is a nanotechnology company developing and commercializing next-gen healthcare solutions in the areas of prevention, detection, and treatment. ZEN is currently focused on commercializing ZENGuardTM, a patent pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The company also has an exclusive agreement to be the global commercializing partner for a newly developed, aptamer-based rapid pathogen detection technology.
For further information:
Greg Fenton, Chief Executive Officer
Tel: 1(437) 220-8140
Email: gfenton@zengraphene.com
About TreborRx Ltd.
TreborRx is a Canadian success story that began when the first wave of COVID hit our country in the winter of 2020. Trebor President Brenda Elliott and CEO George Irwin -- who are life partners as well as business partners -- used their extensive experience in the toy manufacturing sector to pivot and very quickly address critical shortages PPE facing Canadian healthcare workers. In 18 short months, Trebor built a state-of-the art manufacturing facility in Collingwood Ontario and has been highly active in the research and development of superior PPE solutions. Trebor also operates an Alberta PPE manufacturing facility and is entering the international marketplace with Canadian made innovations and products.
For further information:
George Irwin, CEO
Tel: 1(416) 625-7499
Email george.irwin@treborrx.com
To find out more about ZEN Graphene Solutions Ltd., please visit our website at www.ZENGraphene.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.ca.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although ZEN believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. ZEN disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.